--- title: "ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% - Here's Why" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/275092526.md" description: "ADC Therapeutics (NYSE:ADCT) stock fell 4.5% to $3.9050 during mid-day trading, with 740,786 shares traded. Analysts have mixed ratings, with HC Wainwright lowering its price target from $8.00 to $7.00 while maintaining a \"buy\" rating. The company reported a quarterly loss of ($0.30) per share, beating estimates, but revenue was below expectations at $16.43 million. Institutional investors own 41.10% of the stock, and the average price target among analysts is $7.50, indicating a consensus rating of \"Moderate Buy.\"" datetime: "2026-02-06T08:01:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275092526.md) - [en](https://longbridge.com/en/news/275092526.md) - [zh-HK](https://longbridge.com/zh-HK/news/275092526.md) --- > 支持的语言: [English](https://longbridge.com/en/news/275092526.md) | [繁體中文](https://longbridge.com/zh-HK/news/275092526.md) # ADC Therapeutics (NYSE:ADCT) Stock Price Down 4.5% - Here's Why ADC Therapeutics SA (NYSE:ADCT - Get Free Report) was down 4.5% during mid-day trading on Thursday . The company traded as low as $3.88 and last traded at $3.9050. Approximately 740,786 shares were traded during trading, an increase of 12% from the average daily volume of 659,677 shares. The stock had previously closed at $4.09. Get **ADC Therapeutics** alerts: ## Analyst Ratings Changes Several equities analysts recently weighed in on ADCT shares. HC Wainwright dropped their price target on shares of ADC Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research report on Thursday, October 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of ADC Therapeutics in a research note on Wednesday, January 21st. Royal Bank Of Canada restated an "outperform" rating and issued a $5.00 target price on shares of ADC Therapeutics in a report on Wednesday, December 3rd. Wall Street Zen upgraded ADC Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, November 15th. Finally, Guggenheim reissued a "buy" rating and issued a $10.00 price target on shares of ADC Therapeutics in a research report on Wednesday, November 12th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $7.50. **Read Our Latest Stock Analysis on ADC Therapeutics** ## ADC Therapeutics Stock Down 4.5% The firm has a market cap of $483.74 million, a P/E ratio of -2.69 and a beta of 1.93. The firm's 50-day simple moving average is $3.73 and its 200 day simple moving average is $3.67. ADC Therapeutics (NYSE:ADCT - Get Free Report) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.10. The firm had revenue of $16.43 million for the quarter, compared to the consensus estimate of $17.08 million. As a group, analysts forecast that ADC Therapeutics SA will post -1.69 earnings per share for the current year. ## Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of the business. R Squared Ltd bought a new stake in ADC Therapeutics during the 3rd quarter valued at $59,000. Henrickson Nauta Wealth Advisors Inc. bought a new stake in shares of ADC Therapeutics during the 4th quarter valued at $69,000. SG Americas Securities LLC purchased a new stake in ADC Therapeutics during the 4th quarter worth about $86,000. Creative Planning purchased a new stake in ADC Therapeutics during the 2nd quarter worth about $96,000. Finally, Ethic Inc. bought a new position in ADC Therapeutics in the 2nd quarter worth about $103,000. 41.10% of the stock is owned by institutional investors. ## About ADC Therapeutics (Get Free Report) ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity. At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S. ## Further Reading - Five stocks we like better than ADC Therapeutics - NEW LAW: Congress Approves Setup For Digital Dollar? - EXPOSED: The “29% Account” - “Fed Proof” Your Bank Account with THESE 4 Simple Steps - What a Former CIA Agent Knows About the Coming Collapse - Missed Nvidia? Your next 12-month window _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in ADC Therapeutics Right Now? Before you consider ADC Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list. While ADC Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### 相关股票 - [Health Care Select Sector SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [iShares Global Healthcare (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [ADC Therapeutics SA (ADCT.US)](https://longbridge.com/zh-CN/quote/ADCT.US.md) - [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Ark Genomic Revolution ETF (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [iShares US Pharma (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [VG Health (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) - [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) ## 相关资讯与研究 - [Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis | ACRS Stock News](https://longbridge.com/zh-CN/news/279581540.md) - [Pfizer announces positive topline phase 2 results for next-generation CDK4 inhibitor, atirmociclib, in second-line metastatic breast cancer](https://longbridge.com/zh-CN/news/279429425.md) - [Red Light Holland Deploys Kala Bio AI Platform to Advance Psilocybin Drug PEX010](https://longbridge.com/zh-CN/news/279611034.md) - [Novartis Raises $11 Billion to Fund Avidity Biosciences Deal](https://longbridge.com/zh-CN/news/279380374.md) - [Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease](https://longbridge.com/zh-CN/news/279594916.md)